Literature DB >> 7561675

Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1.

P Romero1, C Pannetier, J Herman, C V Jongeneel, J C Cerottini, P G Coulie.   

Abstract

Peptide MAGE-1.A1 is a nonamer derived from protein MAGE-1 that can associate with the HLA-A1 molecule. It was shown previously to be recognized by an antitumor cytolytic T lymphocyte (CTL) clone derived from the blood of melanoma patient MZ2. We derived two other anti-MAGE-1.A1 CTL clones from different blood samples of the same patient and compared the fine specificity of recognition of the three CTL by testing them on variant MAGE-1.A1 peptides incorporating different amino acid substitutions. The epitopes recognized by the CTL proved to be different. While modifications of residues at positions 5, 6, or 7 in the antigenic peptide affected recognition by the three CTL, each of the modifications of residues at positions 1, 4, or 8 affected recognition by one CTL only. The sequences of both the alpha and beta chains of the T cell antigen receptor of the three CTL were completely different. The results indicate a long-lasting diversity in terms of fine specificity and of T cell antigen receptor structure in the repertoire of antitumor CTL derived from the blood of a melanoma patient and directed against a defined tumor antigen.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561675      PMCID: PMC2192298          DOI: 10.1084/jem.182.4.1019

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  47 in total

1.  Highly conserved T-cell receptor junctional regions. Evidence for selection at the protein and the DNA level.

Authors:  S B Sorger; S M Hedrick
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  Monomorphic anti-HLA-A,B,C monoclonal antibodies detecting molecular subunits and combinatorial determinants.

Authors:  F M Brodsky; P Parham
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

4.  Production of stable cytolytic T-cell clones directed against autologous human melanoma.

Authors:  M Hérin; C Lemoine; P Weynants; F Vessière; A Van Pel; A Knuth; R Devos; T Boon
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

5.  Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention.

Authors:  H Acha-Orbea; D J Mitchell; L Timmermann; D C Wraith; G S Tausch; M K Waldor; S S Zamvil; H O McDevitt; L Steinman
Journal:  Cell       Date:  1988-07-15       Impact factor: 41.582

6.  Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy.

Authors:  J L Urban; V Kumar; D H Kono; C Gomez; S J Horvath; J Clayton; D G Ando; E E Sercarz; L Hood
Journal:  Cell       Date:  1988-08-12       Impact factor: 41.582

7.  Presence on a human melanoma of multiple antigens recognized by autologous CTL.

Authors:  B Van den Eynde; P Hainaut; M Hérin; A Knuth; C Lemoine; P Weynants; P van der Bruggen; R Fauchet; T Boon
Journal:  Int J Cancer       Date:  1989-10-15       Impact factor: 7.396

8.  The outline structure of the T-cell alpha beta receptor.

Authors:  C Chothia; D R Boswell; A M Lesk
Journal:  EMBO J       Date:  1988-12-01       Impact factor: 11.598

9.  Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus.

Authors:  V P Argaet; C W Schmidt; S R Burrows; S L Silins; M G Kurilla; D L Doolan; A Suhrbier; D J Moss; E Kieff; T B Sculley; I S Misko
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

10.  Public and private V beta T cell receptor repertoires against hen egg white lysozyme (HEL) in nontransgenic versus HEL transgenic mice.

Authors:  R Cibotti; J P Cabaniols; C Pannetier; C Delarbre; I Vergnon; J M Kanellopoulos; P Kourilsky
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  14 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy.

Authors:  T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

3.  Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.

Authors:  M Sensi; C Farina; C Maccalli; R Lupetti; G Nicolini; A Anichini; G Parmiani; D Berd
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 4.  Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens.

Authors:  P Romero
Journal:  Springer Semin Immunopathol       Date:  1996

5.  Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16.

Authors:  I Melero; M C Singhal; P McGowan; H S Haugen; J Blake; K E Hellstrom; G Yang; C H Clegg; L Chen
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

6.  Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma.

Authors:  P thor Straten; J C Becker; T Seremet; E B Bröcker; J Zeuthen
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

7.  The tumour-associated antigen MAGE-1 is detectable in formalin-fixed paraffin sections of malignant melanoma.

Authors:  F Gudat; M Zuber; U Dürmüller; T Kocher; C Schaefer; C Noppen; G Spagnoli
Journal:  Virchows Arch       Date:  1996-10       Impact factor: 4.064

Review 8.  Oligoclonal T cells in human cancer.

Authors:  E Halapi
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

9.  Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.

Authors:  S L Topalian; M I Gonzales; M Parkhurst; Y F Li; S Southwood; A Sette; S A Rosenberg; P F Robbins
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

10.  Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients.

Authors:  Federico Serana; Alessandra Sottini; Luigi Caimi; Belinda Palermo; Pier Giorgio Natali; Paola Nisticò; Luisa Imberti
Journal:  J Transl Med       Date:  2009-03-24       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.